{
  "question_stem": {
    "en": "A 56-year-old man comes to the emergency department due to right lower extremity pain and swelling. The symptoms began shortly after he flew back to the United States from a 7-day cruise in Indonesia. Doppler ultrasonography reveals a femoropopliteal venous thrombosis, and the patient is given anticoagulation with rivaroxaban. Compared to vitamin K antagonists, this patient's treatment is most likely to have which of the following benefits?",
    "zh": "一名56岁男性因右下肢疼痛和肿胀前来急诊。症状始于他从印度尼西亚为期7天的邮轮旅行返回美国后不久。多普勒超声检查显示股腘静脉血栓形成，患者接受利伐沙班抗凝治疗。与维生素K拮抗剂相比，该患者的治疗最有可能具有以下哪些益处？"
  },
  "question": {
    "en": "Compared to vitamin K antagonists, this patient's treatment is most likely to have which of the following benefits?",
    "zh": "与维生素K拮抗剂相比，该患者的治疗最有可能具有以下哪些益处？"
  },
  "options": {
    "A": {
      "en": "Better patient compliance",
      "zh": "更好的患者依从性"
    },
    "B": {
      "en": "Greater efficacy",
      "zh": "更高的疗效"
    },
    "C": {
      "en": "Less risk of thrombocytopenia",
      "zh": "血小板减少症风险较低"
    },
    "D": {
      "en": "No need for loading dose",
      "zh": "不需要负荷剂量"
    },
    "E": {
      "en": "Less variability in therapeutic effect",
      "zh": "治疗效果的变异性较小"
    }
  },
  "correct_answer": "E",
  "explanation": {
    "en": "Rivaroxaban is a direct oral anticoagulant (DOAC) that binds to and inhibits factor Xa, thereby preventing conversion of prothrombin to thrombin. DOACs are generally preferred over vitamin K antagonists (VKAs) such as warfarin for most conditions requiring prolonged anticoagulation due to less variability in therapeutic effect. The therapeutic effect of VKAs is affected by changes to dietary intake of vitamin K, disruption to vitamin K–producing intestinal flora (eg, antibiotics), and a wide range of medications that inhibit or induce cytochrome P450 2C9; therefore, patients given VKAs require coagulation monitoring (eg, with INR) to ensure adequate anticoagulation. In contrast, the therapeutic effect of DOACs is not typically altered by environmental or medication changes; therefore, laboratory monitoring is not required. DOACs may also have a lower risk of intracranial bleeding, the most serious risk of anticoagulation, when compared to VKAs.\n\n(Choice A) Rates of patient compliance are roughly equivalent for DOACs and VKAs.\n\n(Choices B and C) Heparin can cause thrombocytopenia due to either heparin-induced thrombocytopenia type I (nonimmune mediated) or type 2 (immune mediated). VKAs target vitamin K–dependent clotting factors (not platelets), so they do not typically cause thrombocytopenia. VKAs and DOACs have roughly the same efficacy.\n\n(Choice D) A loading dose is required with heparin. Some DOACs (eg, rivaroxaban) also require a higher dose for the first few weeks prior to initiating a lower maintenance dose. VKAs do not require a loading dose.\n\nEducational objective:\nDirect oral anticoagulants (DOACs) such as rivaroxaban are often preferred over vitamin K antagonists (VKAs) such as warfarin in the treatment of conditions that require anticoagulation due to less variability in therapeutic drug effect; in contrast to VKAs, the efficacy of DOACs is unaffected by dietary changes and most medications. Therefore, patients given DOACs do not require laboratory monitoring.",
    "zh": "利伐沙班是一种直接口服抗凝剂（DOAC），与因子Xa结合并抑制其活性，从而阻止凝血酶原转化为凝血酶。对于大多数需要长期抗凝的疾病，DOAC通常优于维生素K拮抗剂（VKA），如华法林，因为其治疗效果的变异性较小。VKA的治疗效果受维生素K的膳食摄入量变化、破坏维生素K产生菌群（如抗生素）以及多种抑制或诱导细胞色素P450 2C9的药物的影响；因此，接受VKA治疗的患者需要进行凝血监测（如INR），以确保充分的抗凝。相比之下，DOAC的治疗效果通常不受环境或药物变化的影响；因此，不需要实验室监测。与VKA相比，DOAC也可能具有较低的颅内出血风险，这是抗凝治疗最严重的风险。\n\n（选项A）DOAC和VKA的患者依从率大致相当。\n\n（选项B和C）肝素可引起血小板减少症，这可能是由于肝素引起的血小板减少症I型（非免疫介导）或II型（免疫介导）。VKA靶向维生素K依赖性凝血因子（而非血小板），因此通常不会引起血小板减少症。VKA和DOAC的疗效大致相同。\n\n（选项D）肝素需要负荷剂量。一些DOAC（例如，利伐沙班）在开始较低的维持剂量之前，也需要在最初几周内使用较高的剂量。VKA不需要负荷剂量。\n\n教学目标：\n直接口服抗凝剂（DOAC），如利伐沙班，通常在需要抗凝治疗的疾病中优于维生素K拮抗剂（VKA），如华法林，因为其治疗药物效果的变异性较小；与VKA相比，DOAC的疗效不受饮食变化和大多数药物的影响。因此，接受DOAC治疗的患者不需要实验室监测。"
  },
  "summary": {
    "en": "This question tests knowledge of the advantages of direct oral anticoagulants (DOACs) like rivaroxaban compared to vitamin K antagonists (VKAs) such as warfarin, specifically focusing on the variability in therapeutic effect. It assesses understanding of factors affecting VKA efficacy and the implications for monitoring.\n\nThe key to solving this question is recognizing that VKAs are significantly affected by dietary vitamin K intake and drug interactions, leading to variability in their therapeutic effect and requiring regular monitoring. DOACs, on the other hand, have more predictable effects and do not require routine laboratory monitoring.",
    "zh": "本题考察了直接口服抗凝剂（DOAC）如利伐沙班与维生素K拮抗剂（VKA）如华法林相比的优势，特别是侧重于治疗效果的变异性。它评估了对影响VKA疗效的因素及其对监测的影响的理解。\n\n解决此问题的关键是认识到VKA受膳食维生素K摄入量和药物相互作用的显着影响，导致其治疗效果的变异性，并需要定期监测。另一方面，DOAC具有更可预测的效果，不需要常规的实验室监测。"
  },
  "tags": "Rivaroxaban; Direct oral anticoagulants; Vitamin K antagonists; Warfarin; Anticoagulation; Venous thromboembolism; Factor Xa; Therapeutic drug monitoring; Drug interactions; Pharmacology",
  "category": "Blood",
  "question_id": "18686",
  "has_exhibits": false,
  "exhibit_count": 0,
  "exhibit_files": [],
  "folder_path": "C:\\Datas\\usmle\\step1\\clip\\Blood 23\\18686",
  "extracted_at": "2025-11-05T11:28:48.746166",
  "extraction_config": {
    "temperature": 0.1,
    "top_k": 1,
    "prompt_strategy": "standard"
  },
  "translated_at": "2025-11-07T16:29:46.202560",
  "translation_model": "gemini-2.0-flash-lite",
  "embedding_model": "models/embedding-001",
  "embedding_dimension": 768
}